EDMONTON, ALBERTA--(Marketwire - Aug. 4, 2008) - CV Technologies Inc. (TSX:CVQ) - Pediatrics - the official journal of the American Academy of Pediatrics and a prestigious medical journal - has published safety results of a children’s randomized, double-blind, placebo-controlled clinical trial involving COLD-fX®. The trial, designed to measure safety and tolerability, showed COLD-fX is safe for children. It’s the first time COLD-fX has been studied for pediatric use. The results are contained in the August, 2008 issue.
